S. 1852 — Introduced in Senate

II 118th CONGRESS 1st Session S. 1852 IN THE SENATE OF THE UNITED STATES June 7, 2023Mr. Scott of South Carolina (for himself and Mr. Booker) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions A BILL To amend the Public Health Service Act to reauthorize a sickle cell disease prevention and treatment demonstration program. 1. Short title This Act may be cited as the Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023. 2. Sickle cell disease treatment prevention and treatment (a) In general Section 1106(b) of the Public Health Service Act (42 U.S.C. 300b–5(b)) is amended— (1) in paragraph (1)(A)(iii), by striking prevention and treatment of sickle cell disease and inserting treatment of sickle cell disease and the prevention and treatment of complications of sickle cell disease; (2) in paragraph (2)(D), by striking prevention and treatment of sickle cell disease and inserting treatment of sickle cell disease and the prevention and treatment of complications of sickle cell disease; (3) in paragraph (3)— (A) in subparagraph (A), by striking enter into a contract with and inserting make a grant to, or enter into a contract or cooperative agreement with,; and (B) in subparagraph (B), in each of clauses (ii) and (iii), by striking prevention and treatment of sickle cell disease and inserting treatment of sickle cell disease and the prevention and treatment of complications of sickle cell disease; and (4) in paragraph (6), by striking $4,455,000 for each of fiscal years 2019 through 2023 and inserting $8,205,000 for each of fiscal years 2024 through 2028. (b) Sense of Congress It is the sense of Congress that further research should be undertaken to expand the understanding of the causes of, and to find cures for, heritable blood disorders, including sickle cell disease.